CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development	$ 7,428	$ 5,345	$ 19,759	$ 10,844
Research and Development - Related Party	1,000		1,000	250
General and administrative	3,342	1,587	9,027	2,886
Total operating expenses	11,770	6,932	29,786	13,980
Loss from operations	(11,770)	(6,932)	(29,786)	(13,980)
Interest income	466	25	721	42
Other expense	(35)	(36)	(49)	(60)
Net loss	(11,339)	(6,943)	(29,114)	(13,998)
Accretion to redemption value and cumulative dividends on preferred stock		(1,925)	(1,820)	(4,590)
Net loss attributable to common stockholders	$ (11,339)	$ (8,868)	$ (30,934)	$ (18,588)
Net loss per share attributable to common stockholders, basic	$ (0.59)	$ (3.35)	$ (2.21)	$ (7.06)
Net loss per share attributable to common stockholders, diluted	$ (0.59)	$ (3.35)	$ (2.21)	$ (7.06)
Weighted-average number of shares used in computing net loss per share, basic	19,347,148	2,643,879	13,987,862	2,632,919
Weighted-average number of shares used in computing net loss per share, diluted	19,347,148	2,643,879	13,987,862	2,632,919
Other comprehensive income (loss):
Unrealized loss on investments	$ (181)	$ (3)	$ (514)	$ (3)
Comprehensive loss	$ (11,520)	$ (6,946)	$ (29,628)	$ (14,001)